Synergistic Treatment System for Neurodegenerative Diseases
Legal Citation
Summary of the Inventive Concept
A comprehensive system integrating Type I PRMT inhibitors with AI, IoT, and blockchain technologies to enhance treatment outcomes for ALS and FTD patients.
Background and Problem Solved
The original patent addressed the inhibition of dipeptide repeat proteins, but its limitations included the lack of a comprehensive system for diagnosing, treating, and tracking patient outcomes. The present inventive concept addresses this gap by integrating Type I PRMT inhibitors with advanced technologies to create a more effective and personalized treatment approach.
Detailed Description of the Inventive Concept
The system comprises a Type I PRMT inhibitor administration module, an AI-powered diagnostic module for identifying patients with ALS or FTD, and a blockchain-based data storage module for tracking patient treatment outcomes. The system may further include a wearable IoT device for monitoring patient motor neuron activity and transmitting data to the blockchain-based data storage module. The AI-powered predictive model analyzes patient data stored in the blockchain-based data storage module to predict treatment efficacy and identify novel biomarkers for ALS or FTD.
Novelty and Inventive Step
The new claims introduce the synergistic combination of Type I PRMT inhibitors with AI, IoT, and blockchain technologies, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for treating neurodegenerative diseases.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may include the integration of additional technologies, such as machine learning or natural language processing, to further enhance the system's capabilities.
Potential Commercial Applications and Market
The synergistic treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of neurodegenerative disease treatment and personalized medicine. The system's ability to track patient outcomes and predict treatment efficacy makes it an attractive solution for pharmaceutical companies, hospitals, and research institutions.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurological disease treatment technologies, specifically focusing on molecular interventions for neurodegenerative disorders like ALS and FTD, with expertise in protein modification, diagnostic technologies, and medical data management systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in neuroscience, biotechnology, or biomedical engineering, possessing knowledge of molecular therapeutics, AI-driven medical technologies, and data tracking systems for complex neurological conditions
Obviousness Rationale
A PHOSITA would recognize that integrating advanced data management and diagnostic technologies with existing molecular treatment approaches represents a predictable and logical extension of current neurodegenerative disease research. The combination of Type I PRMT inhibitors with AI, IoT, and blockchain technologies provides a systematic approach to enhancing treatment monitoring and personalization. These technological integrations represent incremental improvements that would be apparent to someone skilled in neurological treatment technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,534 |
|---|---|
| Title | Inhibition of dipeptide repeat proteins |
| Assignee(s) | ALS Therapy Development Institute |